STOCK TITAN

[Form 4] Tivic Health Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Tivic Health Systems director Zikria Dean was granted a stock option to purchase 7,500 shares of common stock on 08/06/2025 at an exercise price of $3.32. The option vests in four equal quarterly installments, with 100% vesting upon the first anniversary of the grant, and expires on 08/05/2035. Following the reported transaction the reporting person directly beneficially owns 7,500 derivative securities representing the right to acquire 7,500 shares.

This Form 4 reports a non-cash equity award to an insider: the grant establishes the right to purchase common stock at a fixed price and details the vesting timetable and expiration date.

Il direttore di Tivic Health Systems, Zikria Dean, ha ricevuto un'opzione su azioni per acquistare 7.500 azioni ordinarie il 08/06/2025 a un prezzo di esercizio di $3,32. L'opzione matura in quattro rate trimestrali uguali, con il 100% delle azioni maturate al primo anniversario della concessione, e scade il 08/05/2035. A seguito della transazione segnalata, la persona che effettua la comunicazione detiene direttamente 7.500 strumenti derivati che rappresentano il diritto ad acquisire 7.500 azioni.

Questo Modulo 4 segnala un premio azionario non monetario concesso a un insider: la sovvenzione stabilisce il diritto di acquistare azioni ordinarie a un prezzo fisso e ne dettaglia il calendario di maturazione e la data di scadenza.

La directora de Tivic Health Systems, Zikria Dean, recibió una opción sobre acciones para comprar 7.500 acciones ordinarias el 08/06/2025 a un precio de ejercicio de $3,32. La opción se consolida en cuatro cuotas trimestrales iguales, con el 100% consolidado al primer aniversario de la concesión, y expira el 08/05/2035. Tras la operación comunicada, la persona informante posee directamente 7.500 valores derivados que representan el derecho a adquirir 7.500 acciones.

Este Formulario 4 informa sobre una asignación de capital no dineraria a un insider: la concesión establece el derecho a comprar acciones ordinarias a un precio fijo y detalla el calendario de consolidación y la fecha de vencimiento.

Tivic Health Systems 이사 Zikria Dean은 2025년 08/06일에 보통주 7,500주를 매수할 수 있는 스톡옵션을 행사가 $3.32로 부여받았습니다. 해당 옵션은 동일한 분기별 4회 분할로 권리가 취득되며, 부여일로부터 1주년 시점에 100% 권리 취득이 이루어지고, 만료일은 2035년 08/05일입니다. 신고된 거래 이후 보고인은 보통주 7,500주를 취득할 권리를 나타내는 파생증권 7,500주를 직접적으로 실질 보유하고 있습니다.

이 Form 4는 내부자에 대한 현금이 아닌 주식보상 수여를 보고합니다: 해당 수여는 고정 가격으로 보통주를 매수할 권리를 설정하며 권리 취득 일정과 만료일을 명시합니다.

La directrice de Tivic Health Systems, Zikria Dean, s'est vue accorder le 08/06/2025 une option d'achat portant sur 7 500 actions ordinaires au prix d'exercice de 3,32 $. L'option s'acquiert par quatre trimestres égaux, avec une acquisition à 100 % au premier anniversaire de l'attribution, et expire le 08/05/2035. À la suite de l'opération déclarée, la personne déclarante détient directement 7 500 titres dérivés représentant le droit d'acquérir 7 500 actions.

Ce formulaire 4 signale une attribution d'actions non monétaire à un initié : l'attribution établit le droit d'acheter des actions ordinaires à un prix fixe et précise le calendrier d'acquisition ainsi que la date d'expiration.

Tivic Health Systems-Direktorin Zikria Dean wurde am 08/06/2025 eine Aktienoption zum Kauf von 7.500 Stammaktien zu einem Ausübungspreis von $3,32 gewährt. Die Option wird in vier gleichen vierteljährlichen Raten unverfallbar, wobei 100 % zum ersten Jahrestag der Gewährung unverfallbar sind, und sie verfällt am 08/05/2035. Nach der gemeldeten Transaktion besitzt die meldepflichtige Person direkt 7.500 derivative Wertpapiere, die das Recht zum Erwerb von 7.500 Aktien darstellen.

Dieses Formular 4 meldet eine nicht in bar erfolgte Aktienzuteilung an einen Insider: Die Gewährung begründet das Recht, Stammaktien zu einem festen Preis zu erwerben, und nennt den Vesting-Zeitplan sowie das Ablaufdatum.

Positive
  • Grant of 7,500 stock options to a director is explicitly disclosed
  • Exercise price documented at $3.32, providing clear terms
  • Vesting schedule specified: four equal quarterly installments with full vesting by first anniversary
  • Expiration date provided: 08/05/2035, clarifying option term
Negative
  • None.

Insights

TL;DR: Director received a time‑based option grant of 7,500 shares with full vesting within one year; routine insider compensation disclosure.

The Form 4 documents a standard director equity award: a stock option with an exercise price of $3.32 covering 7,500 shares, vesting in four equal quarterly installments and fully vested by the first anniversary. The option expires on 08/05/2035 and is reported as directly beneficially owned following the acquisition. From a governance perspective this is a routine disclosure that clarifies insider holdings and the schedule under which equity becomes exercisable.

TL;DR: 7,500 options at $3.32 granted to a director; the economical impact depends on company share count and future stock performance.

The filing shows an acquisition coded as an option grant (Transaction Code A) for 7,500 stock options with a $3.32 exercise price, exercisable per the stated quarterly vesting schedule and expiring in 2035. The report confirms direct beneficial ownership of 7,500 derivative securities after the grant. The document provides the core terms investors use to model potential dilution and future insider exercise scenarios, but does not include share count or pro forma dilution figures.

Il direttore di Tivic Health Systems, Zikria Dean, ha ricevuto un'opzione su azioni per acquistare 7.500 azioni ordinarie il 08/06/2025 a un prezzo di esercizio di $3,32. L'opzione matura in quattro rate trimestrali uguali, con il 100% delle azioni maturate al primo anniversario della concessione, e scade il 08/05/2035. A seguito della transazione segnalata, la persona che effettua la comunicazione detiene direttamente 7.500 strumenti derivati che rappresentano il diritto ad acquisire 7.500 azioni.

Questo Modulo 4 segnala un premio azionario non monetario concesso a un insider: la sovvenzione stabilisce il diritto di acquistare azioni ordinarie a un prezzo fisso e ne dettaglia il calendario di maturazione e la data di scadenza.

La directora de Tivic Health Systems, Zikria Dean, recibió una opción sobre acciones para comprar 7.500 acciones ordinarias el 08/06/2025 a un precio de ejercicio de $3,32. La opción se consolida en cuatro cuotas trimestrales iguales, con el 100% consolidado al primer aniversario de la concesión, y expira el 08/05/2035. Tras la operación comunicada, la persona informante posee directamente 7.500 valores derivados que representan el derecho a adquirir 7.500 acciones.

Este Formulario 4 informa sobre una asignación de capital no dineraria a un insider: la concesión establece el derecho a comprar acciones ordinarias a un precio fijo y detalla el calendario de consolidación y la fecha de vencimiento.

Tivic Health Systems 이사 Zikria Dean은 2025년 08/06일에 보통주 7,500주를 매수할 수 있는 스톡옵션을 행사가 $3.32로 부여받았습니다. 해당 옵션은 동일한 분기별 4회 분할로 권리가 취득되며, 부여일로부터 1주년 시점에 100% 권리 취득이 이루어지고, 만료일은 2035년 08/05일입니다. 신고된 거래 이후 보고인은 보통주 7,500주를 취득할 권리를 나타내는 파생증권 7,500주를 직접적으로 실질 보유하고 있습니다.

이 Form 4는 내부자에 대한 현금이 아닌 주식보상 수여를 보고합니다: 해당 수여는 고정 가격으로 보통주를 매수할 권리를 설정하며 권리 취득 일정과 만료일을 명시합니다.

La directrice de Tivic Health Systems, Zikria Dean, s'est vue accorder le 08/06/2025 une option d'achat portant sur 7 500 actions ordinaires au prix d'exercice de 3,32 $. L'option s'acquiert par quatre trimestres égaux, avec une acquisition à 100 % au premier anniversaire de l'attribution, et expire le 08/05/2035. À la suite de l'opération déclarée, la personne déclarante détient directement 7 500 titres dérivés représentant le droit d'acquérir 7 500 actions.

Ce formulaire 4 signale une attribution d'actions non monétaire à un initié : l'attribution établit le droit d'acheter des actions ordinaires à un prix fixe et précise le calendrier d'acquisition ainsi que la date d'expiration.

Tivic Health Systems-Direktorin Zikria Dean wurde am 08/06/2025 eine Aktienoption zum Kauf von 7.500 Stammaktien zu einem Ausübungspreis von $3,32 gewährt. Die Option wird in vier gleichen vierteljährlichen Raten unverfallbar, wobei 100 % zum ersten Jahrestag der Gewährung unverfallbar sind, und sie verfällt am 08/05/2035. Nach der gemeldeten Transaktion besitzt die meldepflichtige Person direkt 7.500 derivative Wertpapiere, die das Recht zum Erwerb von 7.500 Aktien darstellen.

Dieses Formular 4 meldet eine nicht in bar erfolgte Aktienzuteilung an einen Insider: Die Gewährung begründet das Recht, Stammaktien zu einem festen Preis zu erwerben, und nennt den Vesting-Zeitplan sowie das Ablaufdatum.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zikria Dean

(Last) (First) (Middle)
47685 LAKEVIEW BOULEVARD

(Street)
FREMONT CA 94538

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tivic Health Systems, Inc. [ TIVC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Purchase) $3.32 08/06/2025 A 7,500 (1) 08/05/2035 Common Stock 7,500 $0.00 7,500 D
Explanation of Responses:
1. The stock option vests in a series of four (4) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the grant date, such that 100% of the stock option will be vested upon the first anniversary of the grant date.
/s/ Jennifer Ernst, attorney-in-fact 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tivic Health (TIVC) report in this Form 4?

The filing reports that director Zikria Dean was granted a stock option to acquire 7,500 shares, with an exercise price of $3.32 on 08/06/2025.

How does the option vest for the grant reported by TIVC?

The option vests in four equal quarterly installments, rounded down to whole shares, such that 100% vests at the one-year anniversary of the grant.

When does the option expire and how many shares underlie it?

The option expires on 08/05/2035 and is exercisable for 7,500 shares of common stock.

What is the ownership form reported for the derivative securities?

The filing reports the derivative securities as Direct (D) beneficial ownership following the reported transaction.

What transaction code and type are shown on the Form 4 for this grant?

The transaction is coded as A (acquisition) and the derivative security type is listed as Stock Option (Right to Purchase).
Tivic Health Systems Inc

NASDAQ:TIVC

TIVC Rankings

TIVC Latest News

TIVC Latest SEC Filings

TIVC Stock Data

3.45M
765.79k
10.81%
0%
2.64%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
FREMONT